

CLAIMS

1. Use of a fusion protein in the preparation of a pharmaceutical composition for preventing and/or treating pancreatic cancer, characterized in the fusion protein comprises protein MBP and protein MUC1-N, the amino acid sequence of the fusion protein is set forth in SEQ ID NO.3.
5
2. The use according to claim 1, wherein the fusion protein is expressed by connecting the maltose-binding protein MBP gene and the mucin MUC1-N gene in tandem.
3. The use according to claim 1, wherein the nucleotide sequence of the MUC1-N gene is set forth
10 in SEQ ID NO.1, and the nucleotide sequence of the MBP gene is set forth in SEQ ID NO.2.
4. The use according to claim 1, wherein the pharmaceutical composition for preventing and/or treating pancreatic cancer, comprising the fusion protein, an aluminum hydroxide adjuvant, and a CpG adjuvant.
15
5. A pharmaceutical composition for preventing and/or treating pancreatic cancer, comprising a fusion protein, an aluminum hydroxide adjuvant, and a CpG adjuvant, the amino acid sequence of the fusion protein is set forth in SEQ ID NO.3.
- 20 6. The pharmaceutical composition according to claim 4, wherein the CpG adjuvant is partially or fully thio-modified.
7. The pharmaceutical composition according to claim 5, wherein the CpG adjuvant is CpG1826 or fully thio-modified CpG1826.